{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:56:16Z","timestamp":1793987776511,"version":"4.8.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>While liver fibrosis remains a serious, progressive, chronic liver disease, and factors causing damage persist, liver fibrosis may develop into cirrhosis and liver cancer. However, short-term liver fibrosis is reversible. Therefore, an early diagnosis of liver fibrosis in the reversible transition phase is important for effective treatment of liver diseases. Chitinase-3-like protein 1 (CHI3L1), an inflammatory response factor that participates in various biological processes and is abundant in liver tissue, holds promise as a potential biomarker for liver diseases. Here, we aimed to review research developments regarding serum CHI3L1 in relation to the pathophysiology and diagnosis of liver fibrosis of various etiologies, providing a reference for the diagnosis, treatment, and prognosis of liver diseases.<\/jats:p>","DOI":"10.3389\/fmed.2024.1372434","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:23:56Z","timestamp":1718771036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Research advances in serum chitinase-3-like protein 1 in liver fibrosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Xingwei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cld.2023.01.001","article-title":"Nonalcoholic fatty liver disease: disease burden and disease awareness","volume":"27","author":"Golabi","year":"2023","journal-title":"Clin Liver Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12916-014-0159-5","article-title":"The global burden of liver disease: a challenge for methods and for public health","volume":"12","author":"Byass","year":"2014","journal-title":"BMC Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/s0168-8278(02)00429-4","article-title":"Liver fibrosis -- from bench to bedside","volume":"38","author":"Friedman","year":"2003","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"001","DOI":"10.1055\/s-0036-1597816","article-title":"Regression of liver fibrosis","volume":"37","author":"Campana","year":"2017","journal-title":"Semin Liver Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4103\/EUS-D-21-00151","article-title":"Ultrasound elastography","volume":"11","author":"Cui","year":"2022","journal-title":"Endosc Ultrasound"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/jvh.13031","article-title":"China HepB-related fibrosis assessment research group. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients","volume":"26","author":"Dong","year":"2019","journal-title":"J Viral Hepat"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e23200","DOI":"10.1002\/jcla.23200","article-title":"The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases","volume":"34","author":"Jiang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"ref11","first-page":"4090","article-title":"Serum CHI3L1 as a diagnostic marker and risk factor for liver fibrosis in HBeAg-negative chronic hepatitis B","volume":"14","author":"Li","year":"2022","journal-title":"Am J Transl Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.hbpd.2020.05.009","article-title":"Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China","volume":"19","author":"Jin","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3748\/wjg.v11.i4.476","article-title":"Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease","volume":"11","author":"Saitou","year":"2005","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"35282","DOI":"10.1038\/srep35282","article-title":"Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Kumagai","year":"2016","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/j.1572-0241.2006.00610.x","article-title":"Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis","volume":"101","author":"Lieber","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"Xiao","year":"2015","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","article-title":"Accuracy of the enhanced liver fibrosis test vs FibroTest, Elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease","volume":"154","author":"Thiele","year":"2018","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.21037\/apm-21-957","article-title":"A noninvasive diagnostic model for significant liver fibrosis in patients with chronic hepatitis B based on CHI3L1 and routine clinical indicators","volume":"10","author":"Huang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s15010-018-1136-2","article-title":"Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT","volume":"46","author":"Yan","year":"2018","journal-title":"Infection"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.celrep.2013.07.032","article-title":"Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor \u03b12","volume":"4","author":"He","year":"2013","journal-title":"Cell Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17980\/2016.1","article-title":"Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer","volume":"2","author":"Subramaniam","year":"2016","journal-title":"Cancer Res Front"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13046-018-0876-2","article-title":"Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through \u03b2-catenin\/Erk\/Akt signaling in gastric cancer","volume":"37","author":"Geng","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e147552","DOI":"10.1172\/JCI147552","article-title":"Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma","volume":"131","author":"Chen","year":"2021","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/jbmr.5650070506","article-title":"Identification of proteins secreted by human osteoblastic cells in culture","volume":"7","author":"Johansen","year":"1992","journal-title":"J Bone Miner Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.lungcan.2004.11.011","article-title":"Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer","volume":"48","author":"Junker","year":"2005","journal-title":"Lung Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1042\/BJ20131151","article-title":"Chitinase-3-like protein 1 protects skeletal muscle from TNF\u03b1-induced inflammation and insulin resistance","volume":"459","author":"G\u00f6rgens","year":"2014","journal-title":"Biochem J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1042\/BJ20020075","article-title":"The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways","volume":"365","author":"Recklies","year":"2002","journal-title":"Biochem J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"107394","DOI":"10.1016\/j.pharmthera.2019.107394","article-title":"Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases","volume":"203","author":"Yeo","year":"2019","journal-title":"Pharmacol Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.7150\/thno.20183","article-title":"Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice","volume":"8","author":"Jung","year":"2018","journal-title":"Theranostics"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e50826","DOI":"10.1371\/journal.pone.0050826","article-title":"Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway","volume":"7","author":"Sarma","year":"2012","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.7150\/thno.26467","article-title":"Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1","volume":"8","author":"Kim","year":"2018","journal-title":"Theranostics"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e2019633118","DOI":"10.1073\/pnas.2019633118","article-title":"Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis","volume":"118","author":"Nishimura","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fphys.2014.00075","article-title":"Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis","volume":"5","author":"Riabov","year":"2014","journal-title":"Front Physiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/hep.22099","article-title":"Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C","volume":"47","author":"Fontana","year":"2008","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/s0168-8278(00)80095-1","article-title":"Serum YKL-40 is increased in patients with hepatic fibrosis","volume":"32","author":"Johansen","year":"2000","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"E283","DOI":"10.1111\/hepr.12982","article-title":"Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy","volume":"48","author":"Wang","year":"2018","journal-title":"Hepatol Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"36535","DOI":"10.18632\/oncotarget.5440","article-title":"Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9","volume":"6","author":"Low","year":"2015","journal-title":"Oncotarget"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12948-016-0053-0","article-title":"Chitinase 3-like-1 is produced by human Th17 cells and correlates with the level of inflammation in juvenile idiopathic arthritis patients","volume":"14","author":"Capone","year":"2016","journal-title":"Clin Mol Allergy"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/omi.2015.0037","article-title":"CHI3L1 is a liver-enriched, noninvasive biomarker that can be used to stage and diagnose substantial hepatic fibrosis","volume":"19","author":"Huang","year":"2015","journal-title":"OMICS"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1038\/onc.2017.65","article-title":"Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1","volume":"36","author":"Cohen","year":"2017","journal-title":"Oncogene"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13054-020-03383-7","article-title":"COVID-19 clinical investigators of the CHU de Li\u00e8ge. YKL-40 as a new promising prognostic marker of severity in COVID infection","volume":"25","author":"Schoneveld","year":"2021","journal-title":"Crit Care"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.1038\/s41598-022-11532-x","article-title":"Chitinase-3-like protein-1 at hospital admission predicts COVID-19 outcome: a prospective cohort study","volume":"12","author":"De Lorenzo","year":"2022","journal-title":"Sci Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1016\/j.immuni.2023.11.015","article-title":"Chi3l1: new kid on the T cell blockade","volume":"56","author":"He","year":"2023","journal-title":"Immunity"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fern\u00e1ndez","year":"2019","journal-title":"Gastroenterology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","article-title":"The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer","volume":"56","author":"Taifour","year":"2023","journal-title":"Immunity"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5483\/bmbrep.2018.51.5.094","article-title":"Chitinase 3-like-1, a novel regulator of Th1\/CTL responses, as a therapeutic target for increasing anti-tumor immunity","volume":"51","author":"Kim","year":"2018","journal-title":"BMB Rep"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"113082","DOI":"10.1016\/j.expneurol.2019.113082","article-title":"Deletion of Chitinase-3-like 1 accelerates stroke development through enhancement of Neuroinflammation by STAT6-dependent M2 microglial inactivation in Chitinase-3-like 1 knockout mice","volume":"323","author":"Im","year":"2020","journal-title":"Exp Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fimmu.2018.01143","article-title":"Immunomodulation of host Chitinase 3-like 1 during a mammary pathogenic Escherichia coli infection","volume":"9","author":"Breyne","year":"2018","journal-title":"Front Immunol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jcmgh.2023.12.002","article-title":"BRP39 regulates neutrophils recruitment in NLRP3 INFLAMMASOME induced liver inflammation","volume":"17","author":"Kui","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/hepr.13396","article-title":"Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis","volume":"49","author":"Higashiyama","year":"2019","journal-title":"Hepatol Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00109-023-02388-3","article-title":"Correction to: myeloid-specific deletion of chitinase-3-like 1 protein ameliorates murine diet-induced steatohepatitis progression","volume":"101","author":"Kim","year":"2023","journal-title":"J Mol Med (Berl)"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bull World Health Organ"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3760\/cma.j.cn501113-20220209-00060","article-title":"Expert opinion on expanding anti-HBV treatment for chronic hepatitis B","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.008","article-title":"Guidelines for the prevention and treatment of hepatitis C (2019 version)","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.cgh.2022.04.013","article-title":"Fibrosis stage-specific incidence of hepatocellular Cancer after hepatitis C cure with direct-acting antivirals: a systematic review and Meta-analysis","volume":"21","author":"Kim","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"8539804","DOI":"10.1155\/2020\/8539804","article-title":"Decrease in Chitinase 3-like protein 1 levels reflects improvement in liver fibrosis after HCV eradication","volume":"2020","author":"Kang","year":"2020","journal-title":"Dis Markers"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1097\/MEG.0000000000002083","article-title":"Serum fibrosis markers could aid in the prediction of factor for successful oral antiviral treatment in hepatitis C","volume":"33","author":"Sahin","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jvh.13558","article-title":"Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication","volume":"28","author":"Kang","year":"2021","journal-title":"J Viral Hepat"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/iub.2444","article-title":"Chitinase 3-like-1, Tolloid-like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct-acting antivirals","volume":"73","author":"Mangoud","year":"2021","journal-title":"IUBMB Life"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3760\/cma.j.cn501113-20221019-00498","article-title":"The epidemiology and screening of hepatitis D","volume":"30","author":"Xue","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.3748\/wjg.v28.i31.4417","article-title":"Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China","volume":"28","author":"Shen","year":"2022","journal-title":"World J Gastroenterol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"100461","DOI":"10.1016\/j.jhepr.2022.100461","article-title":"Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada","volume":"4","author":"Osiowy","year":"2022","journal-title":"JHEP Rep"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic Steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12020-021-02716-y","article-title":"Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis","volume":"73","author":"He","year":"2021","journal-title":"Endocrine"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2147\/DMSO.S417754","article-title":"Association of non-invasive markers with significant fibrosis in patients with nonalcoholic fatty liver disease: a cross-sectional study","volume":"16","author":"Zhang","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+\u2122, an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/cells10020201","article-title":"Role of Chitinase 3-like 1 protein in the pathogenesis of hepatic insulin resistance in nonalcoholic fatty liver disease","volume":"10","author":"Zhang","year":"2021","journal-title":"Cells"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14309\/ajg.0000000000002778","article-title":"Long-term risks for cirrhosis and hepatocellular carcinoma across Steatotic liver disease subtypes","author":"Chen","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2023.09.010","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"80","author":"Colapietro","year":"2024","journal-title":"J Hepatol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"114520","DOI":"10.1016\/j.biopha.2023.114520","article-title":"Multimodal study of CHI3L1 inhibition and its effect on angiogenesis, migration, immune response and refractive index of cellular structures in glioblastoma","volume":"161","author":"Rusak","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.21037\/atm-21-4537","article-title":"Reciprocal induction of hepatitis C virus replication and stimulation of hepatic profibrogenic cytokine release and cellular viability by YKL-40","volume":"9","author":"Cheng","year":"2021","journal-title":"Ann Transl Med"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12275-014-4267-x","article-title":"The role of microRNAs in hepatitis C virus replication and related liver diseases","volume":"52","author":"Lee","year":"2014","journal-title":"J Microbiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1372434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:24:02Z","timestamp":1718771042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1372434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":83,"alternative-id":["10.3389\/fmed.2024.1372434"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1372434","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"article-number":"1372434"}}